Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Thousands of small fish defy gravity to climb Congo waterfall - 2Dick Van Dyke shares his secrets to longevity as he turns 100
- 3Several injured as man threatens attack on German high-speed train
- 4Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
- 55 Wellbeing Applications Assist You With remaining Fit
- Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- Why are NASA's Artemis astronauts wearing orange? What are they bringing to space? What to know about the preparation for their moon mission.
- The Most Enrapturing Authentic Milestones to Visit
- Josh Duhamel's secret to the good life at 53? Wolverine peptides, ditching Hollywood and having another baby.
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- Astronauts on the ISS watched NASA's historic Artemis 2 launch from space
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- 'Inflaming tensions': Bedouin mayor slams Ben-Gvir's unauthorized visit after meeting cancellation
